Clinical trials: Hepatic Neoplasm
HIV Infections, Hepatitis B
Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population
This is a retrospective study, all HIV-infected individuals followed up at the three designated HIV clinics in Hong Kong with and without HBV and/or HCV co-infection will be included in the analysis.
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma
- Trial name
- NCT03702998
- Where
- Hong Kong
- Volunteers
- 3,900 people
- Sponsor
- Chinese University of Hong Kong
Hepatic Cell Carcinoma
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to…
- Trial name
- NCT06515314
- Testing
- AFP Specific T Cell Receptor T Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ruiliyuan Biotechnology Co., Ltd.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma.
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer
- Trial name
- ELUCIDATE (NCT06342414)
- Testing
- ELUCIDATE
- Where
- 5 sites in United States, Japan
- Volunteers
- 400 people
- Sponsor
- City of Hope Medical Center
Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the…
- Conditions
- Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma
- Trial name
- NCT03232593
- Testing
- Atezolizumab
- Where
- 56 sites in South Korea
- Volunteers
- 1,758 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
- Trial name
- NCT02101593
- Testing
- ADI-PEG 20
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Polaris Group
Colorectal Cancer, Liver Metastases
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
The primary objectives of this phase I/II, prospective clinical trial, are to assess the optimal dose, efficacy, safety and immunological effect of ablation and intra-tumoral injection of a novel immuno-adjuvant (IP-001) for…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer
- Trial name
- INJECTABL-II (NCT06630624)
- Testing
- IP-001
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- M.R. Meijerink
Non Small Cell Lung Cancer, Nasopharyngeal Cancer
Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography
Contrast enhancement ultrasonography（CEUS）could be used to evaluate the blood flow perfusion liver cancer. In this clinical trial, CEUS was used to evaluated the changes of blood flow perfusion of Secondary Malignant Neoplasm of…
- Conditions
- Non Small Cell Lung Cancer, Nasopharyngeal Cancer, Liver Metastasis
- Trial name
- NCT01347424
- Testing
- Paclitaxel , carboplatin, endostatin, Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear.
- Trial name
- NCT01434524
- Testing
- LIVACT
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Kochi University
Liver Neoplasms
Hepatocellular Cancer (HCC) Screening in Zhongshan City
All participants in the selected communities will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be…
- Trial name
- HCC (NCT02501980)
- Testing
- Biomarker testing and Ultrasonography
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Response of Hepatic Tumors to Radioembolization
The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis.
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastasis
- Trial name
- RESRAD (NCT01775280)
- Testing
- Injection of Ytttrium-90 microspheres into the hepatic artery
- Where
- Switzerland
- Sponsor
- University of Zurich
Pancreatic Neoplasms, Cholangiocarcinoma
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Therasphere is a form of treatment that has been designed to selectively deliver radiation to the cancer within the patient's liver.
- Trial name
- NCT01434459
- Testing
- Gemcitabine with TheraSphere
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Liver Transplantation, Hepatocellular Carcinoma
Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
Hepatocellular Carcinoma (HCC) is the most common liver malignancy and the third leading cause of cancer death worldwide. Due to the shortage of donor organs and the risk of tumor recurrence after transplantation, the restrictive…
- Trial name
- NCT05475613
- Testing
- Downstaging procedures containing immunotherapy, Liver transplantation
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma (HCC), DGF
A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocellular Carcinoma: a Nomogram and Machine Learning Approaches.
Background: This study aimed to develop a predictive model for delayed graft function (DGF) in liver transplant patients with hepatocellular carcinoma (HCC) based on preoperative biochemical indicators, using both logistic…
- Trial name
- NCT06626724
- Testing
- Liver transplantation
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Jian You
Advanced Hepatocellular Carcinoma
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.
- Trial name
- NCT05628545
- Testing
- GDKM-100 injection
- Where
- China
- Sponsor
- Guangdong GD Kongming Biotech LLC
Melanoma, Hepatocellular Carcinoma (HCC)
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
- Conditions
- Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H)
- Trial name
- NCT05909995
- Testing
- INCB 99280 with Ipilimumab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Liver Metastases
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
This is an open label fixed dose phase Ib of anti-CEA CAR-T cells hepatic artery infusions and yttrium-90 SIR-Spheres in patients with CEA-expressing liver metastases.
- Trial name
- HITM-SIR (NCT02416466)
- Testing
- anti-CEA CAR-T cells, Sir-Spheres
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roger Williams Medical Center
Hepatocellular Carcinoma
Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma
This project intends to perform CTC PD-L1 imaging, exosomal PD-L1 protein detection, and exosomal LAG-3 protein detection, so as to resolve the functional marker profiles of immunotherapy in the peripheral blood of HCC patients…
- Trial name
- NCT05575622
- Testing
- CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongnan Hospital
Hepatocellular Carcinoma, Narrow Margin
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant simultaneouslyintegrated boost radiotherapy following narrow-margin(<1cm) hepatectomy in patients with HCC.
- Conditions
- Hepatocellular Carcinoma, Narrow Margin, Radiotherapy
- Trial name
- NCT06205472
- Testing
- Adjuvant SIB radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Navigating the Clinical Trial Process for Hepatocellular Carcinoma
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.
- Trial name
- NCT05859945
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.